[Zhaoyan New Drug: Net profit for the first half of 2026 is 748 million yuan, a year-on-year increase of 1126.8%] On August 28, Zhaoyan New Drug (603127.SH) released its 2026 semi-annual report, achieving operating income of 704 million yuan, a year-on-year increase of 5.27%; net profit attributable to shareholders of listed companies was 748 million yuan, a year-on-year increase of 1126.8%. The performance growth was mainly due to the net income of 735 million yuan brought by changes in the fair value of biological assets. Xiaocai's note: The company's Q2 net profit was 509 million. The previous forecast range was 362 million-662 million. Q1 net profit was 238 million. Based on this calculation, Q2 net profit increased by 113% month-on-month.